Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$468M |
| 2 |
Johnson & Johnson
JNJ
|
+$440M |
| 3 |
IBM
IBM
|
+$355M |
| 4 |
Booking.com
BKNG
|
+$332M |
| 5 |
RAI
Reynolds American Inc
RAI
|
+$331M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LLTC
Linear Technology Corp
LLTC
|
+$482M |
| 2 |
Walt Disney
DIS
|
+$247M |
| 3 |
Visa
V
|
+$219M |
| 4 |
Deere & Co
DE
|
+$200M |
| 5 |
Johnson Controls International
JCI
|
+$179M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.02% |
| 2 | Technology | 13.31% |
| 3 | Financials | 12.25% |
| 4 | Industrials | 9.65% |
| 5 | Consumer Staples | 9.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RLH
2101
DELISTED
Red Lions Hotel Corporation
RLH
| $2.58M | ﹤0.01% |
365,300
-59,289
| -14% | -$453K |
|
|
NCOM
2102
DELISTED
National Commerce Corporation
NCOM
| $2.57M | ﹤0.01% |
70,200
+15,500
| +28% | +$574K |
|
|
XCO
2103
DELISTED
Exco Resources
XCO
| $2.56M | ﹤0.01% |
275,800
-15,667
| -5% | -$160K |
|
|
KND
2104
DELISTED
Kindred Healthcare
KND
| $2.56M | ﹤0.01% |
307,052
+47,772
| +18% | +$374K |
|
2105
iShares US Real Estate ETF
IYR
$4.58B
| $2.55M | ﹤0.01% |
32,500
-44,100
| -58% | -$3.44M |
|
2106
Sarepta Therapeutics
SRPT
$1.95B
| $2.55M | ﹤0.01% |
86,078
+37,000
| +75% | +$1.15M |
|
|
NE
2107
DELISTED
Noble Corporation
NE
| $2.55M | ﹤0.01% |
411,600
-1,212,499
| -75% | -$8.16M |
|
|
ENZY
2108
DELISTED
Enzymotec Ltd
ENZY
| $2.54M | ﹤0.01% |
288,700
-1,300
| -0.4% | -$11K |
|
2109
Verastem
VSTM
$604M
| $2.54M | ﹤0.01% |
102,217
+17,034
| +20% | +$271K |
|
2110
Global Industrial
GIC
$1.49B
| $2.54M | ﹤0.01% |
228,594
+17,694
| +8% | +$151K |
|
|
LITS
2111
Lite Strategy Inc
LITS
$30.5M
| $2.53M | ﹤0.01% |
78,221
+28,900
| +59% | +$928K |
|
|
TGA
2112
DELISTED
Transglobe Energy Corp
TGA
| $2.53M | ﹤0.01% |
1,621,400
+17,300
| +1% | +$29K |
|
|
INST
2113
DELISTED
Instructure, Inc.
INST
| $2.51M | ﹤0.01% |
+107,335
| New | +$2.44M |
|
2114
MGP Ingredients
MGPI
$389M
| $2.51M | ﹤0.01% |
+46,300
| New | +$2.18M |
|
2115
TechnipFMC
FTI
$30.1B
| $2.5M | ﹤0.01% |
+103,488
| New | +$2.55M |
|
|
BCRH
2116
DELISTED
BLUE CAPITAL REINSURANCE HOLDINGS LTD.
BCRH
| $2.5M | ﹤0.01% |
129,680
-4,520
| -3% | -$86.6K |
|
|
HDNG
2117
DELISTED
Hardinge Inc
HDNG
| $2.5M | ﹤0.01% |
222,703
-18,697
| -8% | -$203K |
|
2118
Compugen
CGEN
$228M
| $2.5M | ﹤0.01% |
581,236
+46,336
| +9% | +$214K |
|
2119
Napco Security Technologies
NSSC
$1.37B
| $2.5M | ﹤0.01% |
489,144
+10,544
| +2% | +$49.1K |
|
|
SUPV
2120
Grupo Supervielle
SUPV
$738M
| $2.5M | ﹤0.01% |
+146,752
| New | +$2.19M |
|
|
GUID
2121
DELISTED
Guidance Software, Inc.
GUID
| $2.49M | ﹤0.01% |
421,706
+36,006
| +9% | +$246K |
|
|
ITIC
2122
Investors Title Co
ITIC
$534M
| $2.48M | ﹤0.01% |
15,700
+700
| +5% | +$94.8K |
|
2123
Atlanta Braves Holdings Series B
BATRK
$3.41B
| $2.48M | ﹤0.01% |
+104,900
| New | +$2.24M |
|
|
CRHM
2124
DELISTED
CRH Medical Corporation
CRHM
| $2.47M | ﹤0.01% |
301,300
+110,700
| +58% | +$765K |
|
|
EVOL
2125
DELISTED
Evolving Systems, Inc.
EVOL
| $2.47M | ﹤0.01% |
508,449
+15,350
| +3% | +$69K |
|
Similar funds
Jim Simons's Q1 2017 Portfolio in Review
As of Q1 2017, Jim Simons held 3,652 positions worth $71.6B, up 13% from $63.2B the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
Jim Simons deployed $5.19B of net new capital in Q1 2017, opening 433 new positions and adding to 1,585 existing holdings. Its largest new stake was Merck: 7,716,460 shares worth $468M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 12% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Walt Disney, an estimated $247M trimmed.
- Jim Simons's largest Q1 2017 buy was Merck: 7,716,460 shares worth $468M.
- Jim Simons added most to Johnson & Johnson in Q1 2017, an estimated $440M increase.
- Jim Simons's biggest Q1 2017 reduction was Walt Disney, cutting an estimated $247M.
- Jim Simons fully exited Linear Technology Corp in Q1 2017, selling an estimated $482M.
- Jim Simons's ten largest holdings make up 7.9% of its $71.6B portfolio in Q1 2017.
- Jim Simons opened 433 new positions and closed 462 in Q1 2017.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $71.6B.
Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.